Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2007 October; 8(4): 312.
Published online 2007 December 28. doi:  10.1208/pt0804119
PMCID: PMC2750705

Formulation and development of floating capsules of celecoxib: In vitro and in vivo evaluation


The objective of the present study was to develop a hydrodynamically balanced system for celecoxib as single-unit floating capsules. Various grades of low-density polymers were used for formulation of these capsules. The capsules were prepared by physical blending of celecoxib and the polymer in varying ratios. The formulation was optimized on the basis of in vitro buoyancy and in vitro release in citrate phosphate buffer pH 3.0 (with 1% sodium lauryl sulfate). Capsules prepared with polyethylene oxide 60K and Eudragit RL100 gave the best in vitro percentage release and were used as the optimized formulation. By fitting the data into zero-order, first-order, and Higuchi models, we concluded that the release followed zero-order kinetics, as the correlation coefficient (R value) was higher for zero-order release. For gamma scintigraphy studies, celecoxib was radiolabeled with technetium-99m by the stannous reduction method. To achieve the maximum labeling efficiency the process was optimized by studying the reaction at various pH conditions and stannous concentration levels. The radiolabeled complex was added to the optimized capsule, and dissolution studies were performed to ensure that there was no leaching of radioactivity from the capsules. Gamma imaging was performed in rabbits to assess the buoyancy of the optimized formulation. The optimized formulation remained buoyant during 5 hours of gamma scintigraphic studies in rabbits.

Keywords: Celecoxib, single-unit floating capsules, gastroretentive systems, gamma scintigraphy

Full Text

The Full Text of this article is available as a PDF (246K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005;6:E372–E390. doi: 10.1208/pt060347. [PMC free article] [PubMed] [Cross Ref]
2. Sheth PR, Tossounian JL, inventors. Hoffman-La Roche, assignee. Sustained release pharmaceutical capsules. US patent 4 126 672. November 21, 1978.
3. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate system for oral delivery to the GI tract. Adv Drug Del Rev. 1998;34:191–219. doi: 10.1016/S0169-409X(98)00040-4. [PubMed] [Cross Ref]
4. Lenaerts VM, Gurny R. Bioadhesive Drug Delivery Systems. Boca Raton, FL: CRC Press; 1990.
5. Deshpande AA, Shah NH, Rhodes CT, Malick W. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997;14:815–819. doi: 10.1023/A:1012171010492. [PubMed] [Cross Ref]
6. Rednick AB, Tucker SJ, inventors. Sustained release bolus for animal husbandry. US patent 3 507 952. April 22, 1970.
7. Davis SS, Stockwell AF, Taylor MJ, et al. The effect of density on the gastric emptying of single and multiple unit dosage forms. Pharm Res. 1986;3:208–213. doi: 10.1023/A:1016334629169. [PubMed] [Cross Ref]
8. Urguhart J, Theeuwes F, inventors. Alza Corporation, assignee. Drug delivery system comprising a reservoir containing a plurality of tiny pills. US patent 4 434 153. February 28, 1994.
9. Mamajek RC, Moyer ES, inventors. McNeilab, Inc, assignee. Drug dispensing device and method. US patent 4 207 890. June 17, 1980.
10. Fix JA, Cargill R, Engle K. Controlled gastric emptying, III: GRT of a non-disintegrating geometric shape in human volunteers. Pharm Res. 1993;10:1087–1089. doi: 10.1023/A:1018939512213. [PubMed] [Cross Ref]
11. Kedzierewicz F, Thouvenot P, Lemut J, Etinine A, Hoffonan M, Maincene P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release. 1999;58:195–205. doi: 10.1016/S0168-3659(98)00154-0. [PubMed] [Cross Ref]
12. Bechgaard H, Ladefoged K. Distribution of pellets in gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J Pharm Pharmacol. 1978;30:690–692. [PubMed]
13. Paulson SK, Zhang JY, Alan PB, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metabolism Dis. 2000;28:514–521. [PubMed]
14. Chen GL, Hao WH. In vitro performance of floating sustained release capsule of verapamil. Drug Dev Ind Pharm. 1998;24:1067–1072. doi: 10.3109/03639049809089950. [PubMed] [Cross Ref]
15. Shah MV, De Gennaro MD, Suryakarma H. An evaluation of albumin microcapsules prepared using a multiple emulsion technique. J Microencapsul. 1987;4:223–238. doi: 10.3109/02652048709021816. [PubMed] [Cross Ref]
16. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50:874–875. doi: 10.1002/jps.2600501018. [PubMed] [Cross Ref]
17. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation: theoretical considerations. Ind Eng Chem. 1931;23:923–931. doi: 10.1021/ie50260a018. [Cross Ref]
18. Li S, Lin S, Chien TW, Daggy BP, Mirchandani HL. Statistical optimisation of gastric floating system for oral controlled delivery of calcium.AAPS PharmSciTech [serial online]. 2001;2:article 1.
19. Colombo P, Bettini R, Santi P, De Ascentis A, Peppas NA. Analysis of the swelling and release mechanisms from drug delivery systems with emphasis on drug solubility and water transport. J Control Release. 1996;39:231–237. doi: 10.1016/0168-3659(95)00158-1. [Cross Ref]
20. Ritger PL, Peppas NA. A simple equation for description of solute release, I: Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinder or discs. J Control Release. 1987;5:23–26. doi: 10.1016/0168-3659(87)90034-4. [Cross Ref]
21. Korsmeyer RW, Deolkar GEP, Peppas NA. Mechanisms of potassium chloride from compressed, hydrophilic, polymeric matrices: effect of entrapped air. J Pharm Sci. 1983;72:1189–1191. doi: 10.1002/jps.2600721021. [PubMed] [Cross Ref]
22. Desai KGH. Preparation and characteristics of high-amylose com starch/pectin blend microparticles: a technical note. AAPS PharmSciTech. 2005;6:E202–E208. doi: 10.1208/pt060230. [PMC free article] [PubMed] [Cross Ref]
23. Babbar AK, Singh AK, Goel HC, Chauhan UPS, Sharma RK. Evaluation of99mTc-labeled photosan-3, as a hematoporphyrin derivative, as a potential radiopharmaceutical for tumor scintigraphy. Nucl Med Biol. 2000;27:419–426. doi: 10.1016/S0969-8051(00)00092-5. [PubMed] [Cross Ref]
24. Babbar AK, Singh T, Chauhan UPS. A critical evaluation of radiolabeling of glucaric acid with Tc-99m as a potential myocardial infarct imaging radiopharmaceutical. Ind J Nuclear Med. 1996;11:98–103.
25. Maggi L, Bruni R, Conte U. High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. Int J Pharm. 2000;195:229–238. doi: 10.1016/S0378-5173(99)00402-0. [PubMed] [Cross Ref]
26. Pillay V, Fassihi R. Probing the dynamics of matrix hydration in the presence of electrolytes. Drug Deliv. 2001;8:87–92. doi: 10.1080/107175401750177043. [PubMed] [Cross Ref]
27. Costa FO, Sousa JJS, Pais AACC. Comparison of dissolution profiles of ibuprofen pellets. J Control Release. 2003;89:199–212. doi: 10.1016/S0168-3659(03)00033-6. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists